About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

36.73 +36.73 (+1080194.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sionna Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports First Quarter 2026 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch ↗
This biotech innovator in cystic fibrosis therapies reported a notable insider sale amid a year of standout stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
Sionna Short Squeeze Fades As Raymond James Backs Cystic Fibrosis Breakthrough, RBC Warns Treatments Set High Bar ↗
Via Stocktwits
News headline image
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Topline data is on track for anticipated readout in the summer of 2026 
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story ↗
This biotech innovator in cystic fibrosis therapies reported a notable insider sale, as disclosed in recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway. 
Via The Motley Fool
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing. 
Via The Motley Fool
News headline image
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares ↗
After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million ↗
This clinical-stage biotech focused on cystic fibrosis therapies reported a notable insider sale amid a year of sharp ownership reductions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial ↗
Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.